Date

10 January 2017

Location

GoToMeeting

Attendees and Observers

See agenda page

Topics

Welcome, call to order, attendance, conflicts of interest, minutes

JCA welcomed everyone. No changes to the agenda. Attendance (see agenda). No Conflicts declared. Minutes approved. 

Guidelines surrounding use of numbers or roman numerals

GRE said he had been looking at examples and he was most comfortable with the last proposal, doing it as in the literature, because there was no consistency. He said they should go with the diversity, no way to standardize. On whether to represent the alternative number as a synonym, GRE said search engines would not expect to do the transformation, so if users might do it both ways, then the team would have to record both ways. If they are usually represented one way, there was no reason to write the synonym.

BGO said if there is no preference in common usage, then just choose one. JCA suggested using arabic if there is no preference in the literature. The AG members agreed.

As noted on the agenda, "Recommendation: use the most common use in the literature for the FSN. The alternative representation will be included as a synonym if also represented in the literature. If no preference, use the arabic representation."

Clinical genomics

Presentation by Ian Green (IGR). See powerpoint presentation linked to agenda. 

Discussion (27:30): 

PAM said from UK perspective this is quite important and there were strong political imperatives involved, so fast action was needed so that people would not come up with their own, independent solutions. Not mentioned was how tests - LOINC - would interact, which was key due to the IHTSDO/LOINC agreement.

JCA said he realized there were some possible problems with the LOINC agreement but SNOMED International and LOINC would be meeting with soon to discuss the agreement. He said another big topic not mentioned was how to reference external terminologies as values for SNOMED, and whether that was possible or even feasible in the existing environment. GRE suggested looking at linkage tables, which would have to be referenced but he was not sure whether they would be defining or not. He said the strategy and the role SNOMED would play was key. It was a nice start to define what SNOMED CT's role and then could try to align with that.

JCA said it would be a continuing topic on the AG's agenda as the organization tried to take the strategy and realize it as tactical objectives. He expected other groups like modeling to be involved as well. 

PAM said he was due to become involved in the topic next month. NHS Digital would have discussions with SNOMED International in early February. IGR said NHS Digital was focused on rare diseases at the moment, so incredibly interested in Orphanet. 

Drug Model

38:00-45:20 TMO gave a presentation on the drug concept model and products as attributes (see Powerpoint on the agenda page). 

JCA asked a question about reviews of the document with the proposed model and linkage of terms to other standards like IDMP. Do we want to document the separate classes we have with those represented in IDMP? TMO agreed and said she and the drug group would do that. JCA said he just wanted to note the relation between SNOMED and other standards.

JCA also noted that the group was focusing on manufactured form, not administrable form as the focus for this particular model.

47:00-49:00 TMO went on with her presentation on extension of causative agent to include product concepts (same powerpoint).

JCA: one product level concepts cleaned up, can provide clearer ed guidance on use of products for values of relationships. TMO agreed. She said this was a subproduct of the drug work. JCA: part of work of cleaning up the foundational hierarchies. It will be easier to address these hierarchies once foundational hierarchies cleaned up. 

GRE: do you have a set of examples of the type of products you would like to reference? Sometimes we have been using substance when we should have been using product b/c it was manufactured. in case of disorders may get more complicated. Could get in the same position as laterality. Someone has allergy to asperin products and somoen else allergy to asperin substance, so some examples would help so if you could post them after this? TMO: absolutely.

• TMO to post some examples of causative agents for AG review.

JCA: one of the actions is if we want to ask Tech Services to possibly extend the range of the causative agent relationship to include products prior to the cleanup of the hierarchy. He asked TMO if that was premature. TMO said she thought it was. JCA said the action should be deferred until the cleanup of the product hierarchy. The AG agreed. He noted that BGO would be impacted by ECE work. BGO said it was okay - there was a lot of work to do in the area. 

• Adjust prior action regarding Technical Services extending the range of the causative agent relationship to include products to delay such action until after the cleanup of the hierarchy.

ECE Update (Event, Condition and Episode)

55:00 BGO gave a presentation (see powerpoint on agenda page or recording).

1:05 discussion: